Skip to Content

Vertex Pharmaceuticals Inc VRTX

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Narrow-Moat Vertex Reports Strong Q1 Results; Reiterating $259 Fair Value Estimate

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

Vertex Pharmaceuticals reported solid first-quarter results that outperformed FactSet consensus estimates on the top and bottom lines, driven by continued strong execution of its cystic fibrosis franchise. We are maintaining our narrow moat rating and $259 fair value estimate. 

Read Full Analysis

Company Profile

Business Description

Vertex Pharmaceuticals Inc discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. The company's pipeline also includes genetic therapies like CTX001 for beta-thalassemia and sickle-cell disease as well as small-molecule medicines targeting diseases associated with alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease. In addition, Vertex is focusing on developing therapies for pain, type 1 diabetes, inflammatory diseases, influenza, and other rare diseases.

Contact
50 Northern Avenue
Boston, MA, 02210
T +1 617 341-6100
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type Aggressive Growth
Employees 3,400

Related